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high in patients with cirrhosis who develop HCC. 8 Mortality data 
from the UK for HCC demonstrates that this is rising in parallel 
with the incidence rates of HCC such that in 2015 there were 
approximately 1,700 deaths due to HCC. 
 Since cirrhosis is readily identiﬁed and the risk of HCC is known, 
regular surveillance testing using ultrasound scanning is proposed 
to identify HCC early and to facilitate curative treatment. 9 This 
rationale is supported by many international guidelines for the 
management of patients with cirrhosis including the European 
Association for the Study of the Liver (EASL) and the American 
Association for the Study of Liver Diseases (AASLD), as well as by 
recent guidance issued by the National Institute for Health and 
Care Excellence (NICE). 10–12 However, the recommendation that 
patients with cirrhosis have regular surveillance for HCC is not 
universally accepted and the majority of patients do not receive 
surveillance. 13–15 
 The imperative for surveillance 
 Many international authorities, including the AASLD and the EASL 
recommend that high risk groups are entered into surveillance 
programmes. This includes the majority of patients with cirrhosis 
but not those with advanced liver failure unless they are on the 
transplant waiting list. Patients with non-cirrhotic HBV infection 
and patients with HCV infection and advanced ﬁbrosis (deﬁned 
as ﬁbrosis stage 3 [out of 4, where 4 is cirrhosis]) are also 
recommended to have surveillance due to the increased incidence 
of HCC in these groups. 11 Surveillance of individuals without 
cirrhosis will not be discussed further in this article. 
 Surveillance relies on the ideal that if we detect early 
asymptomatic cancers, curative treatment options are 
available to these patients. These treatments include resection, 
transplantation and radiofrequency ablation, each of which can 
achieve 5-year survival rates near 70% for small lesions, <2.5 cm 
in diameter. 9 Recurrent HCC is frequently observed after liver 
resection and ablation since the development of HCC is associated 
with the underlying cirrhosis and that cirrhosis is not treated or 
targeted by local therapies. Liver transplantation offers a real 
prospect of cure for these patients; however, in practice this 
option is limited in applicability due to comorbidity and limited in 
availability due to a shortage of donor organs. 7 
 Current provision of surveillance 
 Reports of HCC surveillance in patients with cirrhosis consistently 
show poor uptake and adherence to the published guidance. A UK 
survey conﬁrmed these international ﬁndings and showed that 
current surveillance for HCC is poor, provision is ad hoc and there 
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 Introduction 
 Hepatocellular carcinoma (HCC) is the 6th most common 
cancer, and the second most common cause of cancer-related 
mortality worldwide. 1 It is recognised as a major complication of 
cirrhosis alongside liver failure. Among individuals with cirrhosis 
and no signs of liver failure, termed ‘compensated cirrhosis’, 
approximately 2–7% develop HCC annually. 2 Over the past 
decade the incidence of HCC has been rising in the UK to a rate of 
3.8 and 1.7 per 100,000 for males and females respectively. 3 
 Globally, HCC is most common in patients with underlying 
chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infection. However, with high rates of alcohol-related liver disease 
(ArLD) and the growing incidence of non-alcoholic fatty liver 
disease (NAFLD), due to the rise in obesity and the metabolic 
syndrome, the incidence of HCC within the UK population is 
expected to continue to increase. 4–6 
 Currently, most individuals with HCC are diagnosed at a late and 
incurable stage when treatment options are limited. 7 In addition, 
the development of HCC in the setting of cirrhosis with or without 
liver failure inevitably increases the risks of intervention and raises 
concerns about treatment suitability. Consequently, mortality is 
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were not standardised recall policies for follow-up of abnormal 
ﬁndings. 16 More speciﬁcally, 131 physicians responded from 156 
units across the UK. Of these, 97% stated that there was a HCC 
surveillance programme available in their hospital but this was not 
supported by later responses in the survey. Seventy-six percent 
stated that this was arranged on an ad hoc basis. Furthermore, 
only 22.6% of respondents said that ultrasonography was 
performed by a radiologist or radiographer with a specialist 
interest in liver disease or knowledge of HCC surveillance. This 
suggests that detection of small lesions by surveillance may not be 
optimal. A further issue which was highlighted by the survey was 
that decision making regarding which patients were deemed high 
risk and entered surveillance was variable between responders. 
Only 36.8% believed that surveillance was cost effective, although 
60.1% thought that outcomes were improved. Respondents were 
further asked about barriers to effective surveillance and reasons 
included access to radiology services, lack of a liver database, 
doubts over effectiveness and patient adherence. Studies from 
the USA echo these ﬁndings and demonstrate that only a minority 
of patients who were at risk underwent surveillance, further 
questioning the effectiveness of surveillance. 15,17 
 Critically, in the UK 30% of patients did not receive written or 
verbal information regarding surveillance. 16 Consequently, patients 
are often not giving informed consent to participation and are 
not aware of its limitations or the frequent need for further 
investigations after an initial abnormal ultrasound scan. This 
too may have an impact on patient compliance with screening 
ultrasonography. 18 
 The overall conclusion from these studies is that the provision of 
HCC surveillance, both in the UK and more widely, is poor. This brings 
into question the effectiveness of the current system of surveillance 
in identifying and enabling treatment of early stage HCC. 
 Possible beneﬁts of surveillance 
 The intended beneﬁts of entering a patient into a surveillance 
programme are clear. The aim is to detect early cancers in at-risk 
groups and enable potentially curative treatments for this group of 
patients. More speciﬁcally, the aim is to detect cancers which are 
less than 2–2.5 cm which can be treated with ablative strategies, 
as treatment in this group has demonstrated signiﬁcant survival 
beneﬁt. 
 While surveillance for HCC in patients with cirrhosis is logical, 
there is limited evidence from randomised controlled trials that 
surveillance for HCC provides survival beneﬁt in this patient 
population. 19,20 A single Chinese randomised controlled trial did 
demonstrate a survival beneﬁt in those screened when compared 
to the control group. 21 However, this study has been criticised due 
to its design and subsequent analysis, 22 and it is likely to have 
overestimated the beneﬁts of surveillance due to these concerns. 
Furthermore, this trial is not readily applicable to a Western 
population with cirrhosis since it included patients with HBV, 
mostly without cirrhosis. Consequently, it is questionable to what 
extent this trial can be relied upon to provide the necessary high-
quality evidence to support surveillance in the UK. 
 Two recent systematic reviews have focused on survival 
beneﬁt/efﬁcacy of 6-monthly ultrasound surveillance. 19,20 
These two reviews, based on the same non-randomised studies 
report conﬂicting interpretations. The ﬁrst pooled the data in 
meta-analysis and suggested that there was clear evidence 
that surveillance improved survival outcomes in patients with 
cirrhosis. 20 The second review did not pool data, recognising 
heterogeneity in study design and in the included patient 
populations, and concluded that while it was possible to achieve 
earlier diagnosis of HCC there was only low level of evidence to 
support a survival beneﬁt from routine surveillance for HCC. 19 
 The non-randomised studies summarised by the two systematic 
reviews do consistently show improvement in outcomes in 
patients with HCC detected in surveillance. The relative reduction 
in mortality is often quoted and is estimated at approximately 
30%. This only tells part of the story. The absolute risk reduction 
in mortality in the highest quality non-randomised studies (those 
that include an estimate of the effect of lead time bias) is in the 
region of 10%. 13,23 To illustrate the impact of this, the number 
of patients  with HCC needed to be in surveillance to prevent one 
death from HCC is 10. This is an underestimate of the number 
of patients  with cirrhosis who would need to be in surveillance. 
Assuming an annual incidence of HCC of 2.5% then 400 patients 
would need to be in surveillance for 10 HCCs to be diagnosed and 
for the one death to be prevented (Fig  1 ). 
 This estimate of the number needed to be in surveillance 
might also allow one to calculate the impact of a coordinated 
surveillance effort at the national level. As an indication of 
the likely impact of a coordinated surveillance effort, there are 
estimated to be in excess of 17,000 new diagnoses of cirrhosis 
annually in the UK 24 and the number of individuals with cirrhosis 
is likely to be in the region of 50,000. 12 If 80% of this group were 
diagnosed with cirrhosis (40,000 individuals) and of these 80% 
were good candidates for surveillance (32,000 individuals), then 
with a number needed to be in surveillance of 400 to prevent one 
death it might be estimated that 80 deaths from HCC would be 
prevented as a consequence. The assumptions made here are 
optimistic and to implement surveillance effectively would require 
 Fig 1.  Illustration of the number of patients required to be in surveil-
lance to prevent one death each year. Individuals under surveillance are 
illustrated. Those without hepatocellular carcinoma (HCC) are shown in grey 
(n=390), those developing HCC are shown in green (n=9), and the individual 
whose death from HCC is prevented is shown in purple (n=1) . 
CMJv18n2S-Rowe.indd   67 4/11/18   5:20 PM
s68 © Royal College of Physicians 2018. All rights reserved.
Anna Roskilly and Ian A Rowe
diagnosis of individuals with cirrhosis before liver failure manifests 
as has been recommended in the NICE cirrhosis guideline. 12 
Currently, only 50% of diagnoses of cirrhosis are made before 
the onset of liver failure 25 and this indicates that the impact of 
surveillance today will be substantially less than the estimate 
above. This clearly identiﬁes the limitations to surveillance as it 
currently stands. 
 Predictable harms of surveillance 
 There is debate as to the effectiveness of surveillance for HCC 
and its impact on overall survival rates. Evidence from randomised 
controlled trials is limited. Few studies focus on the harm to the 
patient, but instead emphasise cost implications of surveillance 
programmes. 
 When considering the risk versus beneﬁts of HCC surveillance 
we must consider the possible harm to the patient. Such concerns 
include false-positive testing resulting in unnecessary and 
risk-associated procedures such as liver biopsy, overdiagnosis 
of HCC among patients with cirrhosis, as well as false-negative 
investigations resulting in delayed diagnosis of HCC. 26 
These factors have the potential to result in both physical 
and psychosocial harm to a patient in surveillance. 18,27 The 
psychosocial harms of surveillance have latterly been addressed 
to a limited extent in the literature. A recent report from the 
USA suggests that up to 75% of patients in surveillance are 
concerned that they will develop HCC and many of these patients 
are concerned that they will die from the disease. In fact, the 
patients included in that study had advanced liver disease and 
50% had evidence of liver failure with limited life expectancy. 18 
Whether surveillance itself was exacerbating the concerns about 
the development of HCC was not investigated but in patients 
with already signiﬁcantly impaired quality of life any adverse 
contribution from surveillance is clearly unwanted. 
 The concern regarding the risk of false-positive scans which 
result in further investigation with magnetic resonance imaging 
(MRI) and computed tomography (CT) has not been explicitly 
addressed. Prospective studies of surveillance 28,29 suggest that up 
to 5% of individuals in surveillance each year have false positive 
tests and additional and unnecessary tests. More recently, it has 
been demonstrated that up to 25% of patients in surveillance 
programmes will experience physical harm from a false-positive 
or indeterminate test including further investigation with CT, 
MRI, angiography or liver biopsy. 27 This lends perspective when 
we consider that only 1–5% of patients with cirrhosis will develop 
HCC and a recent modelling study suggests that many individuals 
entering a surveillance programme will experience harm as a 
result. 30 
 A ﬁnal consideration is the cost effectiveness of surveillance 
programmes in a healthcare system which is underfunded and 
under-resourced at present. Multiple cost-effectiveness studies 
have examined this question and have reported variable ﬁndings 
depending on the incidence as well as the characteristics of 
local health systems. 31 These analyses have not considered 
management of patients after the ﬁrst treatment of HCC and 
this is a signiﬁcant limitation as there are appreciable rates 
of both HCC recurrence and progression of liver disease after 
treatment with resection or radiofrequency ablation; this will 
signiﬁcantly impact future morbidity and mortality. In the recently 
published NICE guidance a new health economic evaluation was 
undertaken. It did not support surveillance at the £20,000 per 
quality-adjusted life year (QALY) threshold that is typically used by 
NICE but the recommendation for surveillance use was justiﬁed on 
the basis that implementation was already widespread. 12 
 Strategies for improvement 
 There are many aspects of the current HCC surveillance 
programme that can be improved, most importantly by including 
those patients who stand to beneﬁt the most and excluding 
those who are unlikely to beneﬁt. It is evident that the balance 
of beneﬁt and harm is dependent on the patient group and so 
careful selection is critical. Therefore, future guidance should 
detail how we deﬁne this at-risk and ideal population. Factors to 
consider include age – younger patients inevitably have more 
life years to gain from early diagnosis of HCC; stage of cirrhosis – 
those with early cirrhosis having more time before end-stage 
liver disease develops; and limited medical comorbidity again 
increasing the likely beneﬁt of surveillance. These factors will be 
key in determining those patients who will be suitable for curative 
treatment options should HCC be detected. In addition, these 
factors also identify patients at low risk of competing mortality, 
both from liver failure as well as from extrahepatic diseases where 
the beneﬁts of surveillance may be greatest. 
 Critically, this strategy may not identify those at the greatest 
risk of developing HCC since it is individuals with very advanced 
liver disease who are at greatest risk. Patients with advanced liver 
disease are often unsuitable for any treatment for HCC other 
than liver transplantation and if this is not available, for whatever 
reason, these individuals should not be offered surveillance. 
 An important factor when considering patients who are 
thought to be potentially appropriate for surveillance is the 
role of informed consent, data for which are now beginning to 
emerge. 30 Consideration also needs to be given to the feasibility 
of implementing surveillance programmes including a specialist 
nursing support, dedicated ultrasound scan lists and same-day 
clinics, alongside maintaining a database of eligible patients with 
cirrhosis. There also needs to be a system in place for recall of 
these patients and management of abnormal test results which is 
currently provided on an ad hoc basis. 
 Although there is a rationale for HCC surveillance, clinicians 
should take care in selecting patients for these programmes 
while evaluating risks versus beneﬁts and considering patient 
wishes. This should enable implementation of a safe and effective 
surveillance programme UK wide, ensuring that those who stand 
to beneﬁt most are included and surveyed appropriately in a cost-
effective manner. ■ 
 References 
 1  GBD 2013 Mortality and Causes of Death Collaborators .  Global, 
regional, and national age-sex specific all-cause and cause-specific 
mortality for 240 causes of death, 1990–2013: a systematic 
analysis for the Global Burden of Disease Study 2013 .  Lancet 
 2015 ; 385 : 117 – 71 . 
 2  Forner  A ,  Llovet  JM ,  Bruix  J .  Hepatocellular carcinoma .  Lancet 
 2012 ; 379 : 1245 – 55 . 
 3  Ladep  NG ,  Khan  SA ,  Crossey  MM  et al.  Incidence and mortality of 
primary liver cancer in England and Wales: changing patterns and 
ethnic variations .  World J Gastroenterol  2014 ; 20 : 1544 – 53 . 
 4  Sheron  N .  Alcohol and liver disease in Europe – Simple measures 
have the potential to prevent tens of thousands of premature 
deaths .  J Hepatol  2016 ; 64 : 957 – 67 . 
CMJv18n2S-Rowe.indd   68 4/11/18   5:20 PM
© Royal College of Physicians 2018. All rights reserved. s69
Surveillance for hepatocellular cancer
 5  Younossi  ZM ,  Koenig  AB ,  Abdelatif  D  et al.  Global epidemiology of 
nonalcoholic fatty liver disease-Meta-analytic assessment of preva-
lence, incidence, and outcomes .  Hepatology  2016 ; 64 : 73 – 84 . 
 6  Younossi  ZM ,  Otgonsuren  M ,  Henry  L  et al.  Association of nonal-
coholic fatty liver disease (NAFLD) with hepatocellular carcinoma 
(HCC) in the United States from 2004 to 2009 .  Hepatology 
 2015 ; 62 : 1723 – 30 . 
 7  Bruix  J ,  Gores  GJ ,  Mazzaferro  V .  Hepatocellular carcinoma: clinical 
frontiers and perspectives .  Gut  2014 ; 63 : 844 – 55 . 
 8  Park  JW ,  Chen  M ,  Colombo  M  et al.  Global patterns of hepatocel-
lular carcinoma management from diagnosis to death: the BRIDGE 
Study .  Liver Int  2015 ; 35 : 2155 – 66 . 
 9  Bruix  J ,  Reig  M ,  Sherman  M .  Evidence-based diagnosis, staging, 
and treatment of patients with hepatocellular carcinoma . 
 Gastroenterology  2016 ; 150 : 835 – 53 . 
 10  Bruix  J ,  Sherman M, American Association for the Study of Liver 
Diseases. Management of hepatocellular carcinoma: an update . 
 Hepatology  2011 ; 53 : 1020 – 2 . 
 11  European Association For The Study Of The Liver, European 
Organisation For Research And Treatment Of Cancer .  EASL-EORTC 
clinical practice guidelines: management of hepatocellular carci-
noma .  J Hepatol  2012 ; 56 : 908 – 43 . 
 12  National Institute for Health and Care Excellence .  Clinical Guideline 
50: Cirrhosis in over 16s: Assessment and management .  NICE , 
 2016 .  www.nice.org.uk/guidance/ng50/evidence/full-guide-
line-2546537581 [ Accessed 12 July 2016 ]. 
 13  Mittal  S ,  Kanwal  F ,  Ying  J  et al.  Effectiveness of surveillance for 
hepatocellular carcinoma in clinical practice: A United States 
cohort .  J Hepatol  2016 ; 65 : 1148 – 54 . 
 14  Singal  AG ,  Nehra  M ,  Adams-Huet  B  et al.  Detection of hepato-
cellular carcinoma at advanced stages among patients in the 
HALT-C trial: where did surveillance fail?  Am J Gastroenterol 
 2013 ; 108 : 425 – 32 . 
 15  Singal  AG ,  Yopp  A ,  Skinner  C  et al.  Utilization of hepatocellular 
carcinoma surveillance among American patients: a systematic 
review .  J Gen Intern Med  2012 ; 27 : 861 – 7 . 
 16  Cross  TJS ,  Villanueva  A ,  Shetty  S  et al.  A national survey of the pro-
vision of ultrasound surveillance for the detection of hepatocellular 
carcinoma  Frontline Gastroenterol  2016 ; 7 : 82 – 9 . 
 17  Davila  JA ,  Henderson  L ,  Kramer  JR  et al.  Utilization of surveillance 
for hepatocellular carcinoma among hepatitis C virus-infected vet-
erans in the United States .  Ann Intern Med  2011 ; 154 : 85 – 93 . 
 18  Farvardin  S ,  Patel  J ,  Khambaty  M  et al.  Patient-reported barriers are 
associated with lower hepatocellular carcinoma surveillance rates 
in patients with cirrhosis .  Hepatology  2017 ; 65 : 875 – 84 . 
 19  Kansagara  D ,  Papak  J ,  Pasha  AS  et al.  Screening for hepatocellular 
carcinoma in chronic liver disease: a systematic review .  Ann Intern 
Med  2014 ; 161 : 261 – 9 . 
 20  Singal  AG ,  Pillai  A ,  Tiro  J .  Early detection, curative treatment, and 
survival rates for hepatocellular carcinoma surveillance in patients 
with cirrhosis: a meta-analysis .  PLoS Med  2014 ; 11 : e1001624 . 
 21  Zhang  BH ,  Yang  BH ,  Tang  ZY .  Randomized controlled trial of 
screening for hepatocellular carcinoma .  J Cancer Res Clin Oncol 
 2004 ; 130 : 417 – 22 . 
 22  Lederle  FA ,  Pocha  C .  Screening for liver cancer: the rush to judg-
ment .  Ann Intern Med  2012 ; 156 : 387 – 9 . 
 23  van Meer  S ,  de Man  RA ,  Coenraad  MJ  et al.  Surveillance for hepa-
tocellular carcinoma is associated with increased survival: Results 
from a large cohort in the Netherlands .  J Hepatol  2015 ; 63 : 1156 –
 63 . 
 24  Ratib  S ,  West  J ,  Crooks  CJ ,  Fleming  KM .  Diagnosis of liver cirrhosis 
in England, a cohort study, 1998–2009: a comparison with cancer . 
 Am J Gastroenterol  2014 ; 109 : 190 – 8 . 
 25  Ratib  S ,  Fleming  KM ,  Crooks  CJ ,  Aithal  GP ,  West  J .  1 and 5 year 
survival estimates for people with cirrhosis of the liver in England, 
1998–2009: a large population study .  J Hepatol  2014 ; 60 : 282 – 9 . 
 26  Heleno  B ,  Thomsen  MF ,  Rodrigues  DS ,  Jorgensen  KJ ,  Brodersen  J . 
 Quantification of harms in cancer screening trials: literature review . 
 BMJ  2013 ; 347 : f5334 . 
 27  Atiq  O ,  Tiro  J ,  Yopp  AC  et al.  An assessment of benefits and harms 
of hepatocellular carcinoma surveillance in patients with cirrhosis . 
 Hepatology  2016 ; 65 : 1196 – 205 . 
 28  Trinchet  JC ,  Bourcier  V ,  Chaffaut  C  et al.  Complications and com-
peting risks of death in compensated viral cirrhosis (ANRS CO12 
CirVir prospective cohort) .  Hepatology  2015 ; 62 : 737 – 50 . 
 29  Trinchet  JC ,  Chaffaut  C ,  Bourcier  V  et al.  Ultrasonographic sur-
veillance of hepatocellular carcinoma in cirrhosis: a randomized 
trial comparing 3- and 6-month periodicities .  Hepatology 
 2011 ; 54 : 1987 – 97 . 
 30  Taylor  EJ ,  Jones  RL ,  Guthrie  JA ,  Rowe  IA .  Modelling the benefits and 
harms of surveillance for hepatocellular carcinoma: information to 
support informed choices .  Hepatology  2017 ; 66 : 1546 – 55 . 
 31  Cucchetti  A ,  Cescon  M ,  Erroi  V ,  Pinna  AD .  Cost-effectiveness of liver 
cancer screening .  Best Pract Res Clin Gastroenterol  2013 ; 27 : 961 –
 72 . 
Address for correspondence: Dr Ian A Rowe, Room 6.1, Clinical 
Sciences Building, University of Leeds, St James’s University 
Hospital, Beckett Street, Leeds LS9 7TF, UK. 
Email:  i.a.c.rowe@leeds.ac.uk 
CMJv18n2S-Rowe.indd   69 4/11/18   5:20 PM
